NCT03430011 · OUTCOME
Number of Participants With Pharmacokinetics Persistence
Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma · Source last updated 2024-05-24
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- Day 29, 60, 90, 180, 270, 365, 545, 730
What was measured
Pharmacokinetics persistence of JCARH125 CAR T cells in the blood as determined by quantitative polymerase chain reaction (qPCR) over time to detect the JCARH125 transgene. Persistence is defined as a transgene count greater than or equal to the lower limit of detection (LLOD).
Analysis population: All participants who have the necessary PK measurements to provide interpretable results for the specific parameters of interest
Groups in this outcome
Phase 1 50 x 10^6 Cells
JCARH125 IV at dose level 50 x 10\^6 consisting of CD3+CAR+T cells
Phase 1 150 x 10^6 Cells
JCARH125 IV at dose level 150 x 10\^6 consisting of CD3+CAR+T cells
Phase 1 300 x 10^6 Cells
JCARH125 IV at dose level 300 x 10\^6 consisting of CD3+CAR+T cells
Phase 1 450 x 10^6 Cells
JCARH125 IV at dose level 450 x 10\^6 consisting of CD3+CAR+T cells
Phase 1 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
Phase 1 Anakinra 600 x 10^6 Cells
2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
Phase 2 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
Phase 2a 600 x 10^6 Cells Anti-BCMA
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
| Group | Source count |
|---|
| Phase 1 50 x 10^6 Cells | 14 |
|---|
| Phase 1 150 x 10^6 Cells | 30 |
|---|
| Phase 1 300 x 10^6 Cells | 26 |
|---|
| Phase 1 450 x 10^6 Cells | 20 |
|---|
| Phase 1 600 x 10^6 Cells | 17 |
|---|
| Phase 1 Anakinra 600 x 10^6 Cells | 14 |
|---|
| Phase 2 600 x 10^6 Cells | 23 |
|---|
| Phase 2a 600 x 10^6 Cells Anti-BCMA | 10 |
|---|
Reported measurements
Day 29
Analysis denominator · Participants
| Group | Source count |
|---|
| Phase 1 50 x 10^6 Cells | 14 |
|---|
| Phase 1 150 x 10^6 Cells | 30 |
|---|
| Phase 1 300 x 10^6 Cells | 26 |
|---|
| Phase 1 450 x 10^6 Cells | 20 |
|---|
| Phase 1 600 x 10^6 Cells | 17 |
|---|
| Phase 1 Anakinra 600 x 10^6 Cells | 14 |
|---|
| Phase 2 600 x 10^6 Cells | 23 |
|---|
| Phase 2a 600 x 10^6 Cells Anti-BCMA | 10 |
|---|
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Phase 1 50 x 10^6 Cells | 14 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 150 x 10^6 Cells | 29 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 300 x 10^6 Cells | 26 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 450 x 10^6 Cells | 20 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 600 x 10^6 Cells | 17 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 Anakinra 600 x 10^6 Cells | 14 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 2 600 x 10^6 Cells | 23 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 2a 600 x 10^6 Cells Anti-BCMA | 10 | Not reported | Not reported | Not reported | Not reported |
|---|
Day 60
Analysis denominator · Participants
| Group | Source count |
|---|
| Phase 1 50 x 10^6 Cells | 12 |
|---|
| Phase 1 150 x 10^6 Cells | 30 |
|---|
| Phase 1 300 x 10^6 Cells | 25 |
|---|
| Phase 1 450 x 10^6 Cells | 17 |
|---|
| Phase 1 600 x 10^6 Cells | 13 |
|---|
| Phase 1 Anakinra 600 x 10^6 Cells | 13 |
|---|
| Phase 2 600 x 10^6 Cells | 22 |
|---|
| Phase 2a 600 x 10^6 Cells Anti-BCMA | 10 |
|---|
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Phase 1 50 x 10^6 Cells | 9 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 150 x 10^6 Cells | 26 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 300 x 10^6 Cells | 21 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 450 x 10^6 Cells | 16 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 600 x 10^6 Cells | 13 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 Anakinra 600 x 10^6 Cells | 12 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 2 600 x 10^6 Cells | 21 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 2a 600 x 10^6 Cells Anti-BCMA | 10 | Not reported | Not reported | Not reported | Not reported |
|---|
Day 90
Analysis denominator · Participants
| Group | Source count |
|---|
| Phase 1 50 x 10^6 Cells | 13 |
|---|
| Phase 1 150 x 10^6 Cells | 24 |
|---|
| Phase 1 300 x 10^6 Cells | 24 |
|---|
| Phase 1 450 x 10^6 Cells | 19 |
|---|
| Phase 1 600 x 10^6 Cells | 11 |
|---|
| Phase 1 Anakinra 600 x 10^6 Cells | 14 |
|---|
| Phase 2 600 x 10^6 Cells | 21 |
|---|
| Phase 2a 600 x 10^6 Cells Anti-BCMA | 8 |
|---|
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Phase 1 50 x 10^6 Cells | 5 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 150 x 10^6 Cells | 16 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 300 x 10^6 Cells | 20 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 450 x 10^6 Cells | 17 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 600 x 10^6 Cells | 9 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 Anakinra 600 x 10^6 Cells | 13 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 2 600 x 10^6 Cells | 18 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 2a 600 x 10^6 Cells Anti-BCMA | 7 | Not reported | Not reported | Not reported | Not reported |
|---|
Day 180
Analysis denominator · Participants
| Group | Source count |
|---|
| Phase 1 50 x 10^6 Cells | 9 |
|---|
| Phase 1 150 x 10^6 Cells | 18 |
|---|
| Phase 1 300 x 10^6 Cells | 21 |
|---|
| Phase 1 450 x 10^6 Cells | 16 |
|---|
| Phase 1 600 x 10^6 Cells | 13 |
|---|
| Phase 1 Anakinra 600 x 10^6 Cells | 10 |
|---|
| Phase 2 600 x 10^6 Cells | 18 |
|---|
| Phase 2a 600 x 10^6 Cells Anti-BCMA | 7 |
|---|
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Phase 1 50 x 10^6 Cells | 2 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 150 x 10^6 Cells | 8 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 300 x 10^6 Cells | 14 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 450 x 10^6 Cells | 12 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 600 x 10^6 Cells | 8 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 Anakinra 600 x 10^6 Cells | 9 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 2 600 x 10^6 Cells | 13 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 2a 600 x 10^6 Cells Anti-BCMA | 4 | Not reported | Not reported | Not reported | Not reported |
|---|
Day 270
Analysis denominator · Participants
| Group | Source count |
|---|
| Phase 1 50 x 10^6 Cells | 7 |
|---|
| Phase 1 150 x 10^6 Cells | 9 |
|---|
| Phase 1 300 x 10^6 Cells | 14 |
|---|
| Phase 1 450 x 10^6 Cells | 8 |
|---|
| Phase 1 600 x 10^6 Cells | 11 |
|---|
| Phase 1 Anakinra 600 x 10^6 Cells | 10 |
|---|
| Phase 2 600 x 10^6 Cells | 14 |
|---|
| Phase 2a 600 x 10^6 Cells Anti-BCMA | 5 |
|---|
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Phase 1 50 x 10^6 Cells | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 150 x 10^6 Cells | 2 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 300 x 10^6 Cells | 9 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 450 x 10^6 Cells | 2 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 600 x 10^6 Cells | 9 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 Anakinra 600 x 10^6 Cells | 7 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 2 600 x 10^6 Cells | 8 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 2a 600 x 10^6 Cells Anti-BCMA | 4 | Not reported | Not reported | Not reported | Not reported |
|---|
Day 365
Analysis denominator · Participants
| Group | Source count |
|---|
| Phase 1 50 x 10^6 Cells | 7 |
|---|
| Phase 1 150 x 10^6 Cells | 7 |
|---|
| Phase 1 300 x 10^6 Cells | 7 |
|---|
| Phase 1 450 x 10^6 Cells | 10 |
|---|
| Phase 1 600 x 10^6 Cells | 12 |
|---|
| Phase 1 Anakinra 600 x 10^6 Cells | 8 |
|---|
| Phase 2 600 x 10^6 Cells | 14 |
|---|
| Phase 2a 600 x 10^6 Cells Anti-BCMA | 5 |
|---|
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Phase 1 50 x 10^6 Cells | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 150 x 10^6 Cells | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 300 x 10^6 Cells | 4 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 450 x 10^6 Cells | 2 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 600 x 10^6 Cells | 6 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 Anakinra 600 x 10^6 Cells | 4 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 2 600 x 10^6 Cells | 8 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 2a 600 x 10^6 Cells Anti-BCMA | 3 | Not reported | Not reported | Not reported | Not reported |
|---|
Day 545
Analysis denominator · Participants
| Group | Source count |
|---|
| Phase 1 50 x 10^6 Cells | 4 |
|---|
| Phase 1 150 x 10^6 Cells | 2 |
|---|
| Phase 1 300 x 10^6 Cells | 6 |
|---|
| Phase 1 450 x 10^6 Cells | 6 |
|---|
| Phase 1 600 x 10^6 Cells | 8 |
|---|
| Phase 1 Anakinra 600 x 10^6 Cells | 3 |
|---|
| Phase 2 600 x 10^6 Cells | 11 |
|---|
| Phase 2a 600 x 10^6 Cells Anti-BCMA | 3 |
|---|
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Phase 1 50 x 10^6 Cells | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 150 x 10^6 Cells | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 300 x 10^6 Cells | 4 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 450 x 10^6 Cells | 4 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 600 x 10^6 Cells | 2 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 Anakinra 600 x 10^6 Cells | 3 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 2 600 x 10^6 Cells | 3 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 2a 600 x 10^6 Cells Anti-BCMA | 2 | Not reported | Not reported | Not reported | Not reported |
|---|
Day 730
Analysis denominator · Participants
| Group | Source count |
|---|
| Phase 1 50 x 10^6 Cells | 0 |
|---|
| Phase 1 150 x 10^6 Cells | 2 |
|---|
| Phase 1 300 x 10^6 Cells | 4 |
|---|
| Phase 1 450 x 10^6 Cells | 3 |
|---|
| Phase 1 600 x 10^6 Cells | 6 |
|---|
| Phase 1 Anakinra 600 x 10^6 Cells | 3 |
|---|
| Phase 2 600 x 10^6 Cells | 5 |
|---|
| Phase 2a 600 x 10^6 Cells Anti-BCMA | 1 |
|---|
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Phase 1 50 x 10^6 Cells | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 150 x 10^6 Cells | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 300 x 10^6 Cells | 2 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 450 x 10^6 Cells | 2 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 600 x 10^6 Cells | 4 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 1 Anakinra 600 x 10^6 Cells | 2 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 2 600 x 10^6 Cells | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
| Phase 2a 600 x 10^6 Cells Anti-BCMA | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 14
- group Id
- OG001
- value
- 29
- group Id
- OG002
- value
- 26
- group Id
- OG003
- value
- 20
- group Id
- OG004
- value
- 17
- group Id
- OG005
- value
- 14
- group Id
- OG006
- value
- 23
- group Id
- OG007
- value
- 10
- denoms
- counts
- group Id
- OG000
- value
- 14
- group Id
- OG001
- value
- 30
- group Id
- OG002
- value
- 26
- group Id
- OG003
- value
- 20
- group Id
- OG004
- value
- 17
- group Id
- OG005
- value
- 14
- group Id
- OG006
- value
- 23
- group Id
- OG007
- value
- 10
- units
- Participants
- title
- Day 29
- categories
- measurements
- group Id
- OG000
- value
- 9
- group Id
- OG001
- value
- 26
- group Id
- OG002
- value
- 21
- group Id
- OG003
- value
- 16
- group Id
- OG004
- value
- 13
- group Id
- OG005
- value
- 12
- group Id
- OG006
- value
- 21
- group Id
- OG007
- value
- 10
- denoms
- counts
- group Id
- OG000
- value
- 12
- group Id
- OG001
- value
- 30
- group Id
- OG002
- value
- 25
- group Id
- OG003
- value
- 17
- group Id
- OG004
- value
- 13
- group Id
- OG005
- value
- 13
- group Id
- OG006
- value
- 22
- group Id
- OG007
- value
- 10
- units
- Participants
- title
- Day 60
- categories
- measurements
- group Id
- OG000
- value
- 5
- group Id
- OG001
- value
- 16
- group Id
- OG002
- value
- 20
- group Id
- OG003
- value
- 17
- group Id
- OG004
- value
- 9
- group Id
- OG005
- value
- 13
- group Id
- OG006
- value
- 18
- group Id
- OG007
- value
- 7
- denoms
- counts
- group Id
- OG000
- value
- 13
- group Id
- OG001
- value
- 24
- group Id
- OG002
- value
- 24
- group Id
- OG003
- value
- 19
- group Id
- OG004
- value
- 11
- group Id
- OG005
- value
- 14
- group Id
- OG006
- value
- 21
- group Id
- OG007
- value
- 8
- units
- Participants
- title
- Day 90
- categories
- measurements
- group Id
- OG000
- value
- 2
- group Id
- OG001
- value
- 8
- group Id
- OG002
- value
- 14
- group Id
- OG003
- value
- 12
- group Id
- OG004
- value
- 8
- group Id
- OG005
- value
- 9
- group Id
- OG006
- value
- 13
- group Id
- OG007
- value
- 4
- denoms
- counts
- group Id
- OG000
- value
- 9
- group Id
- OG001
- value
- 18
- group Id
- OG002
- value
- 21
- group Id
- OG003
- value
- 16
- group Id
- OG004
- value
- 13
- group Id
- OG005
- value
- 10
- group Id
- OG006
- value
- 18
- group Id
- OG007
- value
- 7
- units
- Participants
- title
- Day 180
- categories
- measurements
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 2
- group Id
- OG002
- value
- 9
- group Id
- OG003
- value
- 2
- group Id
- OG004
- value
- 9
- group Id
- OG005
- value
- 7
- group Id
- OG006
- value
- 8
- group Id
- OG007
- value
- 4
- denoms
- counts
- group Id
- OG000
- value
- 7
- group Id
- OG001
- value
- 9
- group Id
- OG002
- value
- 14
- group Id
- OG003
- value
- 8
- group Id
- OG004
- value
- 11
- group Id
- OG005
- value
- 10
- group Id
- OG006
- value
- 14
- group Id
- OG007
- value
- 5
- units
- Participants
- title
- Day 270
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 1
- group Id
- OG002
- value
- 4
- group Id
- OG003
- value
- 2
- group Id
- OG004
- value
- 6
- group Id
- OG005
- value
- 4
- group Id
- OG006
- value
- 8
- group Id
- OG007
- value
- 3
- denoms
- counts
- group Id
- OG000
- value
- 7
- group Id
- OG001
- value
- 7
- group Id
- OG002
- value
- 7
- group Id
- OG003
- value
- 10
- group Id
- OG004
- value
- 12
- group Id
- OG005
- value
- 8
- group Id
- OG006
- value
- 14
- group Id
- OG007
- value
- 5
- units
- Participants
- title
- Day 365
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 4
- group Id
- OG003
- value
- 4
- group Id
- OG004
- value
- 2
- group Id
- OG005
- value
- 3
- group Id
- OG006
- value
- 3
- group Id
- OG007
- value
- 2
- denoms
- counts
- group Id
- OG000
- value
- 4
- group Id
- OG001
- value
- 2
- group Id
- OG002
- value
- 6
- group Id
- OG003
- value
- 6
- group Id
- OG004
- value
- 8
- group Id
- OG005
- value
- 3
- group Id
- OG006
- value
- 11
- group Id
- OG007
- value
- 3
- units
- Participants
- title
- Day 545
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 2
- group Id
- OG003
- value
- 2
- group Id
- OG004
- value
- 4
- group Id
- OG005
- value
- 2
- group Id
- OG006
- value
- 1
- group Id
- OG007
- value
- 1
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 2
- group Id
- OG002
- value
- 4
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 6
- group Id
- OG005
- value
- 3
- group Id
- OG006
- value
- 5
- group Id
- OG007
- value
- 1
- units
- Participants
- title
- Day 730
- denoms
- counts
- group Id
- OG000
- value
- 14
- group Id
- OG001
- value
- 30
- group Id
- OG002
- value
- 26
- group Id
- OG003
- value
- 20
- group Id
- OG004
- value
- 17
- group Id
- OG005
- value
- 14
- group Id
- OG006
- value
- 23
- group Id
- OG007
- value
- 10
- units
- Participants
- description
- Pharmacokinetics persistence of JCARH125 CAR T cells in the blood as determined by quantitative polymerase chain reaction (qPCR) over time to detect the JCARH125 transgene. Persistence is defined as a transgene count greater than or equal to the lower limit of detection (LLOD).
- groups
- description
- JCARH125 IV at dose level 50 x 10\^6 consisting of CD3+CAR+T cells
- id
- OG000
- title
- Phase 1 50 x 10^6 Cells
- description
- JCARH125 IV at dose level 150 x 10\^6 consisting of CD3+CAR+T cells
- id
- OG001
- title
- Phase 1 150 x 10^6 Cells
- description
- JCARH125 IV at dose level 300 x 10\^6 consisting of CD3+CAR+T cells
- id
- OG002
- title
- Phase 1 300 x 10^6 Cells
- description
- JCARH125 IV at dose level 450 x 10\^6 consisting of CD3+CAR+T cells
- id
- OG003
- title
- Phase 1 450 x 10^6 Cells
- description
- JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
- id
- OG004
- title
- Phase 1 600 x 10^6 Cells
- description
- 2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells
- id
- OG005
- title
- Phase 1 Anakinra 600 x 10^6 Cells
- description
- JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
- id
- OG006
- title
- Phase 2 600 x 10^6 Cells
- description
- JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy
- id
- OG007
- title
- Phase 2a 600 x 10^6 Cells Anti-BCMA
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- All participants who have the necessary PK measurements to provide interpretable results for the specific parameters of interest
- reporting Status
- POSTED
- time Frame
- Day 29, 60, 90, 180, 270, 365, 545, 730
- title
- Number of Participants With Pharmacokinetics Persistence
- type
- SECONDARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle